Apogee Starts Phase 2 Trial of APG777 in Atopic Dermatitis with First Patient Dosed. APG777 is a new long-acting IL-13 inhibitor for treating Atopic Dermatitis and various inflammatory conditions.

Voyager Therapeutics, Inc. revealed that the initial subjects have been administered doses in a Phase 1a single ascending dose study of VY-TAU01.

Tourmaline Bio Begins Clinical Trials for TOUR006 in Cardiovascular Disease; First Patient Treated in Phase 2 TRANQUILITY Study.

CASI Pharmaceuticals Gets FDA Approval For Investigational New Drug CID-103 In Treating Immune Thrombocytopenia (ITP).

Ractigen Therapeutics Gains NMPA Clearance to Begin Phase 1 Trials of RAG-17 in Chinese SOD1-ALS Patients.

With Weekly Dosing, Insulin Efsitora Alfa Achieves A1C Reduction and Matches Safety of Daily Insulin.

Biopharmaceutical firm Iterion Therapeutics has initiated a Phase 1b/2a clinical trial for its lead drug candidate, tegavivint, which is designed to inhibit Transducin beta-like protein 1 (TBL1).

Immune-Onc Therapeutics has entered into a clinical trial collaboration with Roche to assess the potential of IO-108 as a first-line treatment for hepatocellular carcinoma (HCC).

NextPoint Therapeutics has initiated a Phase 1 clinical trial for NPX887, a drug designed to target solid tumors with high expression of the HHLA2/B7-H7 antigen.

Monopar Therapeutics Inc. has been given the green light by the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 dosimetry study for its innovative radiopharmaceutical, MNPR-101-Zr.

Arvinas Inc. has initiated its Phase 1 clinical trial of ARV-102, a novel oral PROTAC® protein degrader aimed at treating neurodegenerative diseases.

Aleta Biotherapeutics, a company specializing in immuno-oncology, has initiated a Phase 1/2 clinical trial for its innovative biologic, ALETA-001.